24/7 Patient Assistance: 760-405-8205

Brian W. Loggie, MD

Surgical Oncologist

Write a review
Doctor's profile photo

Request a call back

Conditions Treated Ovarian Cancer Pericardial Mesothelioma Pleural Mesothelioma Testicular Mesothelioma

specialties & services

  • Bio & Insurance Information

    A native of Montreal, Canada, Dr. Brian Loggie completed the courses of Loyola College and graduated from the McGill University Medical School. He completed his residency at the Montreal General Hospital and moved to Chicago afterwards to complete a fellowship at the University of Illinois. Currently the chief of the surgical oncology division at the Creighton University Medical Center, Dr. Brian Loggie’s specialty and main focus is mesothelioma. As a surgical oncologist, Dr. Loggie has been well respected in the field for the last several decades, and uses highly effective techniques for treating mesothelioma and any damage this causes through minimally invasive surgical interventions. He is board certified in surgical oncology.

  • Education & Training


    Loyola College, Montreal, Canada - 1974



    McGill University, Montreal, Canada - 1979

    Medical School


    Montreal General Hospital, Montreal, Canada (1980-1986)



    University of Illinois at Chicago, Chicago, Illinois (1986-1988)


  • Board Certifications

    American Board of Surgery

  • Hospital & Practice

    Boys Town National Research Hospital

    Languages: English/Spanish

    (402) 498-6511

    555 North 30th Street

    Omaha, Nebraska 68131

    Read More

    Creighton University Medical Center

    Languages: English/Spanish

    (402) 449-4000

    601 North 30th Street

    Omaha, Nebraska 68131

    Read More
  • Publications & Memberships

    Dr. Brian W. Loggie has contributed to 3 publications.

    Comparison of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with mitomycin or carboplatin for diffuse malignant peritoneal mesothelioma.

    Shetty SJ, Bathla L, Govindarajan V, Thomas P, Loggie BW.

    See more >>

    Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma.

    Foster JM, Radhakrishna U, Govindarajan V, Carreau JH, Gatalica Z, Sharma P, Nath SK, Loggie BW.

    See more >>

    Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma.

    Foster JM, Gatalica Z, Lilleberg S, Haynatzki G, Loggie BW.

    See more >>


    Society of Surgical Oncology

    American College of Surgeons

    American Medical Association

    American Society of Clinical Oncology

    Association for Academic Surgery

Verified Patient Reviews

Rate This Doctor

June 25, 2016

by Michele K.

Wait Time




“Twenty years ago when I was 49 I found out that I had a rare form of cancer and only 6 months to live. I was referred to Dr. Loggie and became his patient in his NIH study using hot chemo. I could not have had a better doctor to guide me through this difficult road. Dr. Loggie never gave up on me, even when I felt like quitting.”